Overactive bladder (OAB) is a chronic syndrome defined by symptoms of urinary urgency with no underlying medical causes. First-line treatment of OAB comprises fluid intake advice and bladder training, supplemented by anticholinergic drugs if necessary. Owing to the chronic nature of OAB, the ideal anticholinergic treatment should have good long-term efficacy and tolerability. There are many anticholinergics available, although some of these are not specific for the bladder and can cause adverse effects such as dry mouth, constipation, blurred vision or cognitive impairment. Imidafenacin (a newer anticholinergic which has been marketed in Japan since 2007) was developed to improve the tolerability of anticholinergic therapy. This article summarizes the pharmacological properties, pharmacokinetics, clinical efficacy and tolerability of imidafenacin in the treatment of OAB. Data from key clinical studies of imidafenacin show that it has a fast onset of action and is effective for the treatment of OAB. It selectively binds to muscarinic receptors in the bladder and is associated with a good safety profile compared with other anticholinergics. The clinical efficacy, superior tolerability and adjustable dosing of imidafenacin make it a good anticholinergic for the treatment of OAB.
Introduction
Overactive bladder (OAB) is a chronic syndrome defined by symptoms of urinary urgency with no underlying medical causes [Abrams et al. 2002] . The most prevalent symptom is urinary urgency which is generally accompanied by urinary frequency and nocturia, or urgency incontinence [Abrams et al. 2002] . OAB is a common disease with an overall prevalence of at least 16% in adults in the USA and Europe [Milsom et al. 2001; Stewart et al. 2003 ]. In Japan, the incidence of OAB in men and women aged at least 40 years is 12.4% ]. Furthermore, OAB is strongly correlated with age; for example, the incidence of OAB in older people (≥70 years old) in Japan exceeds 30% . OAB is associated with a reduced quality of life and influences the social, psychological, occupational, daily living, physical and sexual aspects of a patient's life [Abrams et al. 2000 ].
First-line treatment of OAB comprises fluid intake advice and bladder training, supplemented by anticholinergic drugs if necessary. As OAB is a chronic disease, anticholinergics should be chosen based on long-term efficacy and safety. There are a variety of anticholinergic drugs available in Japan for the treatment of OAB: solifenacin succinate, tolterodine tartrate, propiverine, oxybutynin chloride and imidafenacin (Table 1) . While these all act on muscarinic receptors, they have different tolerability profiles. Those which are not specific for the bladder cause adverse effects such as dry mouth, constipation, blurred vision or cognitive impairment [Andersson, 2004] . In comparison, imidafenacin (a newer anticholinergic which has been marketed in Japan since 2007) was developed to improve the tolerability of anticholinergic therapy by being specific for the M3 receptor subtype which is found mainly in the bladder [Andersson, 2004] . This article provides an overview of the pharmacokinetics, pharmacological properties, clinical efficacy and tolerability of imidafenacin in the treatment of OAB, including our experience in the LIST study. [Kobayashi et al. 2007b; Ohtake et al. 2008; Yamazaki et al. 2011 
Pharmacokinetics
Details of the key phase I trials of imidafenacin are summarized in Table 2 .
Imidafenacin has a short half-life and undergoes urinary excretion within 24 h of administration (with the exception of its M-4 metabolite which is excreted within 48 h) [Shimada et al. 2007d ]. Plasma half-life values for single oral doses of imidafenacin 0.025, 0.05, 0.1, 0.25 or 0.5 mg in healthy volunteers were 2.6-3.0 h [Shimada et al. 2007d] . Although it has been suggested that a short half-life could contribute to an unacceptable tolerability profile, this was not the case with imidafenacin. In this single-dose pharmacokinetic trial imidafenacin had an acceptable tolerability profile [Shimada et al. 2007d ].
After repeated doses of imidafenacin there was no drug accumulation in healthy volunteers [Shimada et al. 2007b ]. Oral imidafenacin 0.25 mg twice daily for 5 days had a peak plasma concentration (C max ) and pharmacokinetic parameters comparable to those after the initial dose [Shimada et al. 2007b ]. This lack of accumulation means that adverse events can be easily managed. In case of urinary retention, symptoms are easily reduced by stopping treatment. In contrast, urinary retention symptoms induced by other anticholinergic treatments with a long half-life (such as solifenacin) can persist after treatment cessation [Zaitsu et al. 2011] .
The pharmacokinetics of imidafenacin are not greatly influenced by food or age. In the fed versus fasted state, the area under the plasma concentration-time curve from time 0 to 12 h (AUC 0-12 ) and C max increased by about 1.3 and 1.2 times, respectively [Shimada et al. 2007a] . A single oral dose of imidafenacin 0.1 mg in healthy older men showed that the C max of imidafenacin was about 1.2 times higher than that in younger patients (determined in an earlier study) [Shimada et al. 2007d ], while the AUC from time 0 to infinity (AUC 0-∞ ) was similar between patient groups [Shimada et al. 2007c ]. Data suggest that there is no need to adjust the imidafenacin dose in patients with lowered metabolic function; whether it is due to age, sex or metabolic enzyme genotype [Shimada et al. 2007c ].
Finally, the metabolites of imidafenacin have no pharmacological activity [Kobayashi et al. 2007a] . A preclinical study showed that, while imidafenacin has a high affinity for the muscarinic acetylcholine receptor subtypes, its metabolites (M-2, M-4 and M-9) had low affinity for these receptor subtypes [Kobayashi et al. 2007a ].
Imidafenacin selectivity
Involuntary contractions of the detrusor muscle, the smooth muscle wall of the bladder, via the action of acetylcholine at the muscarinic receptor (in particular at the M2 and M3 receptor subtypes) is presumed to be the main cause of OAB [Wein, 2001; Chapple et al. 2002; Andersson, 2004] . The M2 receptor is the main cholinergic receptor in the urinary bladder; however, its function is not well defined [Wein, 2001; Chapple et al. 2002; Andersson, 2004] . Conversely, the M3 receptor is known to be directly involved with detrusor muscle contraction [Wein, 2001; Chapple et al. 2002; Andersson, 2004] . Muscarinic receptors also mediate gastrointestinal motility (M3), salivary gland function (M1, M3), heart rate and cardiac output (M2), cognitive processing (M1) and contraction of the ciliary muscle in the eye (M3) [Herbison et al. 2003; Andersson, 2004] . 
No adverse events or changes in laboratory values were reported M-2 metabolite:
C max 159 pg/ml T max (median) 2.0 h t ½ 3.6 h Urinary excretion 6.6% *Doses of 0.1, 0.25 and 0.5 mg only AE, adverse event; ALT, alanine transaminase; AST, aspartate transaminase; AUC 0-12 , area under the plasma concentration-time curved from time 0 to 12 h; AUC 0-∞ , area under the plasma concentration-time curved from time 0 to infinity; CL/F, apparent total clearance; C max , peak plasma concentration; PK, pharmacokinetic; t ½ , half-life; T max , time to peak plasma concentration; Vd/F, apparent volume of distribution. Anticholinergics available for the treatment of OAB can either be nonselective or selective for one or more muscarinic receptor subtype (Table 1) . This selectivity affects each drug's tolerability profile because anticholinergic drugs that are not specific for the bladder can cause adverse effects such as dry mouth, constipation, blurred vision or cognitive impairment [Andersson, 2004] .
Bladder
Imidafenacin is the most bladder-selective anticholinergic available: it antagonizes both the M3 and M1 receptor subtypes in vitro and in vivo [Kobayashi et al. 2007a [Kobayashi et al. , 2007b Yamada et al. 2011b ]. Furthermore, preclinical research indicates that the duration of receptor binding of imidafenacin is longer in the bladder than in the salivary glands, heart, colon and brain [Kobayashi et al. 2007a [Kobayashi et al. , 2007b Yamada et al. 2011b ].
Brain
Imidafenacin does not bind to muscarinic receptors in the brain. After intravenous administration in rats, neither imidafenacin nor darifenacin showed significant binding to muscarinic receptors in the brain whereas an injection of oxybutynin was associated with brain muscarinic receptor binding . In contrast to oxybutynin, imidafenacin also did not reduce cognitive function in a Morris water maze task in rats [Kobayashi et al. 2007b ].
Similar findings have been reported in clinical studies. In patients with OAB due to neurological diseases, imidafenacin increased bladder volume at first sensation together with increasing oxyhemoglobin concentration in the frontal micturition area, with no cognitive decline [Sakakibara et al. 2011 ]. Furthermore, imidafenacin has been used effectively and safely for the treatment of OAB in patients with chronic stroke indicating that imidafenacin is associated with a good safety profile in neurological disorders [Kaneko et al. 2011 ].
Finally, while cognitive adverse events with the anticholinergic tolterodine are rare because it has limited entry into the brain, some cases of central nervous system adverse events have been reported [Diefenbach et al. 2008] . A retrospective analysis showed that these central nervous system adverse events are associated with mutations on one or both cytochrome P450 2D6 (CYP2D6) alleles [Diefenbach et al. 2008] . Unlike tolterodine, imidafenacin is not metabolized by CYP2D6 [Kanayama et al. 2007 ], so central nervous system adverse events are not expected.
Heart
Normally, the muscarinic M2 receptor subtype mediates a decrease in heart rate, which is associated with bradycardia and decreased cardiac output [Andersson, 2004] . Therefore, antagonism of M2 receptors may lead to an increase in heart rate [Andersson, 2004] , as seen for propiverine, an anticholinergic which nonselectively inhibits M2 [Abrams et al. 2006 ]. In comparison, imidafenacin does not appear to have any effect on the heart.
In a phase III, randomized controlled trial investigating the efficacy and tolerability of imidafenacin 0.1 mg twice daily and propiverine 20 mg/day in patients with OAB, there was no significant change from baseline in the QTc interval in imidafenacin recipients (-1.37 ± 21.53 ms), whereas propiverine was associated with a significant increase in the QTc interval (+7.56 ± 20.08 ms; p < 0.0001) ]. Furthermore, imidafenacin was not associated with a significant change from baseline in heart rate; whereas heart rate significantly (p < 0.0001) increased in patients receiving propiverine (-0.8 ± 9.6 beats per minute [bpm] versus +4.4 ± 9.2 bpm) .
Salivary
Imidafenacin is a potent inhibitor of salivary secretion. A preclinical study showed that imidafenacin was associated with a strong inhibition of the acetylcholine-induced K + efflux from the salivary gland: only darifenacin was associated with more effective inhibition (darifenacin > imidafenacin > oxybutynin ≥ tolterodine > pirenzepine ≥ propiverine > methoctramine) [Kobayashi et al. 2007a ]. Furthermore, imidafenacin potently and dose-dependently inhibited carbamylcholinestimulated salivary secretion in rats [Kobayashi et al. 2007b] . Again, only darifenacin was associated with more effective inhibition [Kobayashi et al. 2007b ]. However, this study also indicated that, while imidafenacin potently inhibits salivary secretion, it has an 8.8-fold preference for the muscarinic receptors in the bladder responsible for distention-induced rhythmic bladder contraction (desired effect) over the muscarinic receptors responsible for salivary secretion (associated with dry mouth).
The selectivity of imidafenacin for the salivary gland was demonstrated in humans in a study conducted in 18 medical centers in Tokyo. This study showed that while imidafenacin was associated with the shortest amount of time to the development of dry mouth, it was associated with the fastest resolution of dry mouth symptoms 1 month after drug administration, compared with solifenacin, tolterodine or propiverine [Kase et al. 2010 ].
Colon
The standard dose of imidafenacin (0.1 mg twice daily) shows little to no binding to muscarinic receptors in the colon whereas higher doses of imidafenacin have a short duration of binding to the colon [Yamada et al. 2011a ]. In comparison, while low-dose tolterodine does not bind to muscarinic receptors in the colon, high-dose tolterodine is associated with a long duration of binding to these muscarinic receptors [Yamada et al. 2011a] . Tolterodine is generally well tolerated with low rates of constipation reported [Takei and Homma, 2005] ; however, in patients who are low metabolizers, the long duration of binding in the colon may lead to significant gastrointestinal adverse events.
Imidafenacin has a short half-life and has a short duration of muscarinic receptor binding, which leads to a period of time between imidafenacin administrations (a 'resting phase') when the drug has no antimuscarinic action in the colon. In comparison, anticholinergics with a long duration of muscarinic receptor binding, like solifenacin or propiverine, have no such 'resting phase'. Furthermore, solifenacin is associated with a long duration of binding to the colon and propiverine has been shown to bind to muscarinic receptors in the colon longer than in the bladder which increases the risk of these drugs, inducing constipation [Yamada et al. 2011a ].
The timing of constipation also differs among anticholinergics. Time-dependent differences in the severity and incidence of adverse events between imidafenacin and solifenacin were observed in the LIST study (see efficacy and tolerability section for trial details) [Zaitsu et al. 2011] . While there was no difference in the incidence of constipation between imidafenacin and solifenacin in patients who received treatment for at least 12 weeks (log rank test: p = 0.0621) (data on file), the incidence of constipation over the long term (52 weeks) was significantly higher in solifenacin recipients (log rank test: p = 0.0017) [Zaitsu et al. 2011 ].
Meek and colleagues conducted a meta-analysis investigating the relationship between anticholinergics used for the treatment of OAB and constipation [Meek et al. 2011] . They reported that the risk of constipation differed among drugs, and this variation may depend on differences in affinity for muscarinic receptors [Meek et al. 2011 ].
Of the anticholinergics analyzed (darifenacin, fesoterodine, oxybutynin, trospium, solifenacin and tolterodine), solifenacin was associated with the highest risk of constipation [odds ratio (OR) compared with placebo 3.02, 95% confidence interval (CI) 2.37-3.84], whereas tolterodine was associated with the lowest risk of constipation (OR 1.36, 95% CI 1.01-1.85) [Meek et al. 2011 ].
Efficacy and tolerability
Primary clinical trials Key clinical trial design features and outcomes for studies investigating the use of imidafenacin in OAB are summarized in Table 3 .
Phase II. One phase II, randomized, doubleblind, placebo-controlled, dose-finding study investigating the efficacy and tolerability of imidafenacin was conducted in 401 Japanese patients with OAB . Patients were randomized to oral imidafenacin 0.05, 0.1 and 0.25 mg twice daily or placebo.
Imidafenacin reduced urgency incontinence, voiding frequency and urinary urgency compared with placebo. Furthermore, the number of incontinence episodes (primary endpoint) in patients receiving imidafenacin 0.1 and 0.25 mg twice daily was significantly and dose-dependently reduced (p < 0.0001) compared with placebo .
Imidafenacin was generally well tolerated, with the incidences of adverse events following a dosedependent pattern ]. The most common adverse event was dry mouth. Constipation, nasopharyngitis, abnormal sensations in the eye, dyspepsia, dizziness and vomiting were also reported .
Considering the balance between the efficacy and safety of imidafenacin, a dose of 0.1 mg twice daily appeared to be a clinically appropriate dose for treating OAB. This dose was therefore selected for further evaluation in large-scale phase III studies.
Phase III. Three phase III trials investigating imidafenacin for the treatment of OAB have been published Yamaguchi, 2008, 2009; Yamaguchi and Homma, 2009 ]. The first was a randomized, double-blind, placebo-and propiverine-controlled trial which investigated the efficacy and tolerability of imidafenacin in 781 Japanese patients with OAB ]. Patients were randomized to oral imidafenacin 0.1 mg twice daily, oral propiverine 20 mg once daily or placebo.
This study showed that imidafenacin was not inferior to propiverine for the reduction of incontinence episodes. Imidafenacin and propiverine significantly reduced the number of incontinence episodes per week versus placebo (-68.24% and -73.09% versus -49.50%, respectively; both p < 0.0001) . Similar reductions in urgency incontinence, voiding frequency and urinary urgency were also observed in patients who received imidafenacin and propiverine. Imidafenacin was well tolerated and associated with a significantly lower incidence of adverse events compared with propiverine (p = 0.0101) ]. The most common adverse event was dry mouth: reported in 31.5% and 39.9% of patients receiving imidafenacin and propiverine, respectively (p = 0.0302
).
An open-label study investigating the long-term tolerability and efficacy of imidafenacin 0.1 mg twice daily showed that the favorable safety, tolerability and efficacy observed with imidafenacin was maintained over 52 weeks in 478 Japanese patients with OAB . Again, the most commonly reported adverse event was dry mouth (40.2% of patients) . In this study, 41 serious adverse events and one death in 35 patients were reported . Forty of the serious adverse events were considered not related to the study drug; whereas one serious adverse event (acute glaucoma) was considered possibly related to imidafenacin . The death (ischemic cardiac failure resulting from concurrent hypertension) was considered not related to the study drug .
Another open-label study investigating the longterm tolerability and efficacy of imidafenacin 0.2 mg twice daily was conducted in 435 Japanese patients with OAB who did not have an adequate respond to imidafenacin 0.1 mg twice daily . At the higher dosage, imidafenacin was relatively well tolerated, with dry mouth and constipation reported in 53.3% and 18.7% of patients receiving 0.2 mg twice daily and 26.5% and 9.9% of patients receiving 0.1 mg twice daily, respectively ]. Furthermore, imidafenacin 0.2 mg twice daily improved the number of urgency incontinence episodes per week after 16 weeks of treatment compared with 0.1 mg twice daily . The authors concluded that if the effect of imidafenacin 0.1 mg twice daily is insufficient, a dose increase to 0.2 mg twice daily could be effective and safe, providing additional options for managing patients who are not satisfied with the effect of the standard dose of imidafenacin .
Other clinical trials
Overactive bladder. The LIST study was a randomized, open-label, 52-week study comparing the efficacy and tolerability of imidafenacin (0.1 mg twice daily) and solifenacin (5 mg once daily) in patients with OAB [Zaitsu et al. 2011] .
The results showed no significant difference between the two anticholinergics in terms of efficacy over 12 and 52 weeks, but the severity and incidence of drug-induced adverse events differed between treatment groups (Table 4 ) [Zaitsu et al. 2011] . The severity of dry mouth associated with imidafenacin was significantly milder than that in solifenacin recipients: four patients (20%) receiving solifenacin reported severe dry mouth compared with none receiving imidafenacin [Zaitsu et al. 2011] . Furthermore, the incidence of constipation was also significantly (p = 0.0013) lower with imidafenacin than solifenacin [Zaitsu et al. 2011] .
The authors proposed that the differences in the observed tolerability of these two anticholinergics may be due to differences in pharmacokinetics and binding selectivity [Zaitsu et al. 2011] .
Nocturia. Nocturia, the need to get up in the night to urinate, is a common symptom of OAB. A number of studies investigating the effects of imidafenacin on nocturia and sleep quality have been conducted [Takeda et al. 2009; Nagaoka et al. 2011; Shimizu et al. 2011; Kuratsukuri et al. 2012] , which highlight that imidafenacin is a viable option for improving sleep quality and duration in patients with OAB and nocturia.
The Evaluation of Anticholinergics in Patients with OAB and Nocturia for Cared-health (EPOC) study investigated the effects of imidafenacin 0.1 mg twice daily on sleep in patients with OAB [Takeda et al. 2009 ]. This study found that after 8 weeks of treatment there was a correlation between the improvement observed in nocturia, assessed using a frequency volume chart, and sleep quality, assessed using the Pittsburgh Sleep Quality Index (PSQI; correlation coefficient 0.358) [Takeda et al. 2009 ].
This was supported by the FUSION study which investigated the effects of imidafenacin on sleep disorders and health-related quality of life (HRQOL) in patients with OAB and nocturia [Nagaoka et al. 2011] . Imidafenacin was associated with improved sleep parameters and HRQOL.
The GOOD-NIGHT study investigated the efficacy and tolerability of imidafenacin and α-blocker therapy in men with benign prostatic hyperplasia and OAB [Kuratsukuri et al. 2012] . This open-label study in 130 men who had been receiving an α-blocker for at least 4 weeks and were experiencing nocturia randomized patients to an α blocker alone, an α blocker with Dry mouth the time to the first adverse event caused by solifenacin increased after 12 weeks, but not by imidafenacin(log rank test: p = 0.0412). Constipation the time to the first adverse event caused by solifenacin increased after 12 weeks, but not by imidafenacin(log rank test: p = 0.0017).
Blurred vision
No significant difference between treatment groups (log rank test: p = 0.0686) AE, adverse event; KHQ, King's Health Questionnaire; OABSS, overactive bladder symptoms score.
imidafenacin 0.1 mg twice daily or an α blocker with imidafenacin 0.1 mg once daily [Kuratsukuri et al. 2012 ]. Adding imidafenacin 0.1 mg twice daily and 0.1 mg once daily (administered in the evening) to α-blocker therapy was associated with a reduction in night-time voiding (p = 0.0014 and 0.0143) and an improvement in Nocturia Quality Of Life Questionnaire scores (p = 0.0013 in imidafenacin 0.1 mg twice daily group only) after 8 weeks of treatment compared with α-blocker therapy alone [Kuratsukuri et al. 2012 ].
Finally, a study in 140 older patients with OAB showed that imidafenacin 0.1 mg twice daily improved nocturnal polyuria after 4 weeks of treatment [Shimizu et al. 2011] . In patients aged 65-74 years and patients aged at least 75 years, imidafenacin was associated with a significant (p < 0.001) reduction in the Overactive Bladder Symptom Score (OABSS) [Shimizu et al. 2011] .
Benign prostatic hyperplasia. Imidafenacin has demonstrated utility for the management of symptoms in patients with benign prostatic hyperplasia and OAB. The GOOD-NIGHT study found that adding imidafenacin 0.1 mg twice daily and 0.1 mg once daily to α-blocker therapy not only improved nocturia (as discussed previously) but was also associated with an improvement in International Prostate Symptom Score Quality of Life (IPSS-QOL) scores (p = 0.0040 and 0.0038) after 8 weeks of treatment compared with α-blocker therapy alone [Kuratsukuri et al. 2012] .
Women. Imidafenacin improved OAB symptoms and quality of life, assessed using the OABSS and the International Consultation on Incontinence Questionnaire -Short Form, respectively, in a trial investigating the efficacy and safety of imidafenacin in women with urge and mixed urinary incontinence [Shimada et al. 2011b ]. Imidafenacin was also well tolerated [Shimada et al. 2011b] : no serious adverse events were reported and the incidence of any adverse event was low (7.9%).
Older people. Unpublished results from phase II and phase III, double-blind, placebo-controlled trials indicate that age does not appear to influence the efficacy or tolerability of imidafenacin. Furthermore, in a prospective clinical trial in 140 patients with OAB who received imidafenacin 0.1 mg twice daily for 4 weeks, there was no difference between patients aged 65-74 years old and patients aged at least 75 years with regards to the reduction in OABSS scores (from 8.5 ± 3.2 to 5.2 ± 3.4 and from 8.9 ± 3.0 to 5.5 ± 3.1, respectively; both p < 0.001) [Shimizu et al. 2011] .
Clinical benefits of imidafenacin: a summary
Imidafenacin is clinically effective Imidafenacin has been shown to be a potent anticholinergic in in vitro studies [Kobayashi et al. 2007a , Yamada et al. 2011b ]. Furthermore, in a phase III clinical trial, imidafenacin was associated with a significant improvement in OAB compared with placebo: this benefit was similar (not inferior) to the efficacy of propiverine 20 mg/ day in this trial . Imidafenacin is also associated with a similar efficacy to solifenacin. In the Global Assessment Study of Anti-cholinergics on Efficacy and Tolerability for Patients with OAB study, both imidafenacin and solifenacin were associated with significant improvements in the total and four subscores of the OABSS [Nishii et al. 2011 ]: the LIST study showed similar results [Zaitsu et al. 2011 ]. Finally, the efficacy of imidafenacin for the treatment of OAB is immediate: efficacy is observed 3 days after the initiation of treatment [Kubota et al. 2010; Kitagawa et al. 2011] .
Imidafenacin is safe and well tolerated for long-term treatment Studies have demonstrated that imidafenacin is associated with a favorable short-term tolerability profile compared with propiverine ] and a favorable long-term tolerability profile compared with solifenacin [Zaitsu et al. 2011 ]. In addition, in a study conducted by Kase and colleagues, imidafenacin was associated with the shortest duration of dry mouth symptoms compared with other anticholinergics [Kase et al. 2010] .
Adjustable dosing
One unique feature of imidafenacin treatment is the ability to easily adjust dosing. Some patients with OAB only experience symptoms during part of the day. Imidafenacin is given as a twice-daily oral tablet and this enables treatment to be administered at a time most suitable to target the symptoms when they happen. For example, in patients with nocturia, 0.3 mg/day imidafenacin can be administered as 0.1 mg in the morning and 0.2 mg in the evening. Furthermore, a new oral disintegrating tablet formulation has been developed that allows for administration without water [Shimada et al. 2011a] , which could help patients to control drinking behavior and limit fluid intake.
Conclusions
OAB is a chronic disease. Therefore, the ideal treatment should have good long-term efficacy and tolerability. Imidafenacin meets these criteria, making it is a useful anticholinergic for the treatment of OAB.
